RxDoctor Payments Data

Tauseef Sarguroh, MD

Nephrology · Olympia Fields, ILNPI 1235442443

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $121,594 of the $143,814 with a category attached, or 84.5%. 35 manufacturers reported payments, led by Bayer at 48.8% of the total. 2025 is the largest year on record at $88,478, more than ten times the $375 reported in 2019. Among nephrology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$143,814in general payments, 2019–2025

Across 431 payments — averaging $333.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$70K
  • Novo Nordisk$67K
  • AstraZeneca$933
  • Amgen$903
  • Mallinckrodt Hospital Products Inc.$788
  • OPKO Pharmaceuticals, LLC$380
  • plus $3K from 29 others

What the payments were for

  • Consulting fees$1,3491%
  • Speaking & faculty fees$121,59485%
  • Travel & lodging$9,2156%
  • Food & beverage$11,2788%
  • Education$3780%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$143,814 in reported general payments places this provider in the 95th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$306,071
Medicare patients
564
Services billed
2,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol90$54,861
KerendiaFinerenone30$25,755
JardianceEmpagliflozin22$17,175
Sevelamer Carbonate17$3,304
Calcium Acetate15$1,232
Bumetanide26$1,024
Losartan Potassium56$289
Furosemide53$252
Allopurinol17$191
Carvedilol30$182
Zolpidem Tartrate16$174
Hydralazine Hcl12$155
Amlodipine Besylate24$99
Prednisone21$93
Spironolactone11$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$933$54,86190 claims
BayerKerendia$70,200$25,75530 claims
Boehringer IngelheimJardiance$167$17,17522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 524 nephrology providers in Illinois.

Other nephrology in Olympia Fields

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →